[{"orgOrder":0,"company":"Valinor Pharma","sponsor":"Grunenthal","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2024","type":"Acquisition","leadProduct":"Naloxegol Oxalate","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Valinor Pharma","amount2":0.25,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Valinor Pharma \/ Grunenthal","highestDevelopmentStatusID":"14","companyTruncated":"Valinor Pharma \/ Grunenthal"}]

Find Clinical Drug Pipeline Developments & Deals by Valinor Pharma

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : Through the acquisition, Grunenthal will leverage the Valinor pipeline, which also includes Movantik (naloxegol), indicated for the treatment of OIC in adult patients with chronic non-cancer pain.

                          Brand Name : Movantik

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          July 22, 2024

                          Lead Product(s) : Naloxegol Oxalate

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Discovery

                          Sponsor : Grunenthal

                          Deal Size : $250.0 million

                          Deal Type : Acquisition

                          blank